Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Miransertib (ARQ-092) 是一种具有口服活性的,选择性和变构性Akt 抑制剂。它有效抑制利什曼原虫,还是 AKT1-E17K 突变蛋白抑制剂,可研究PI3K/AKT 驱动的肿瘤和 Proteus 综合征。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 447 | 现货 | ||
5 mg | ¥ 882 | 现货 | ||
10 mg | ¥ 1,430 | 现货 | ||
25 mg | ¥ 2,890 | 现货 | ||
50 mg | ¥ 4,620 | 现货 | ||
100 mg | ¥ 7,390 | 现货 | ||
500 mg | ¥ 14,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 992 | 现货 |
产品描述 | Miransertib (ARQ-092) is an orally bioavailable, selective, and potent allosteric Akt inhibitor. |
靶点活性 | Akt3:8.1 nM, Akt2:14 nM, Akt1:2.7 nM |
体外活性 | ARQ 092 blocks membrane translocation of inactive AKT and even dephosphorylates the membrane-associated active form, thereby perturbing AKT activity. Treatment with 50-500 nM ARQ 092 significantly blocks αMβ2 integrin function in neutrophils and reduces P-selectin exposure and glycoprotein Ib/IX/V-mediated agglutination in platelets[2]. In a large panel of diverse cancer cell lines, ARQ 092 inhibits proliferation across multiple tumor types but are most potent in leukemia, breast, endometrial, and colorectal cancer cell lines. Moreover, inhibition by ARQ 092 is more prevalent in cancer cell lines containing PIK3CA/PIK3R1 mutations compared to those with wt-PIK3CA/PIK3R1 or PTEN mutations[1]. ARQ 092 targets the PI3K/AKT pathway and AKT specifically and reduces phosphorylation of GSK3α and GSK3β in mutation-positive cells[3]. |
细胞实验 | Cells (MDA-MB-453: 1.5×106; NCI-H1650: 1×106; KU-19-19: 0.7×106) are plated into 6 well plates, left overnight, and then treated with full media containing different concentrations (0, 0.012, 0.037, 0.11, 0.33, and 1 μM) of AKT inhibitors (ARQ 092, ARQ 751, MK-2206, GDC-0068) for 2 hours. Cells are treated under designated conditions and lysates are extracted. Proteins are resolved from extracts using SDS-PAGE followed by immunoblotting. (Only for Reference) |
别名 | ARQ-092, AKT inhibitor 2 |
分子量 | 432.52 |
分子式 | C27H24N6 |
CAS No. | 1313881-70-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (115.6 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.312 mL | 11.5602 mL | 23.1203 mL | 57.8008 mL |
5 mM | 0.4624 mL | 2.312 mL | 4.6241 mL | 11.5602 mL | |
10 mM | 0.2312 mL | 1.156 mL | 2.312 mL | 5.7801 mL | |
20 mM | 0.1156 mL | 0.578 mL | 1.156 mL | 2.89 mL | |
50 mM | 0.0462 mL | 0.2312 mL | 0.4624 mL | 1.156 mL | |
100 mM | 0.0231 mL | 0.1156 mL | 0.2312 mL | 0.578 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Miransertib 1313881-70-7 Cytoskeletal Signaling Microbiology/Virology PI3K/Akt/mTOR signaling Parasite Akt anti-proliferative PKB Akt1 Protein kinase B Inhibitor ARQ092 Akt3 AKT1-E17K Akt2 inhibit ARQ-092 p-PRAS40 ARQ 092 anti-tumor p-Akt AKT inhibitor 2 inhibitor